CANCER.

Information on current developments in both regular and alternative or complementary treatments for cancer types and resources at all stages. We have basically all articles and information put in alphabetical order, scroll in left column in alphabetical list.

Experiences of cancer patients with complementary approaches can be found by experience stories and there are also some videos of experiences of cancer patients to see. To click on video button top left . Or visit the website of the SNFK information where movies are shown on complementary approaches to cancer.

Diagnosis of colorectal cancer: M2-PK is an enzyme that occurs in the faeces - relief and the development / presence of bowel cancer predicted

September 14, 2004: Source: British Journal of Cancer (2004) 91, 980-984. doi: 10.1038/sj.bjc.6602033 Published online 13 July 2004

Researchers have discovered that in the faeces - relief - human colon cancer with a fabric-specific enzyme called M2-PK over-represented in the faeces compared to people who do not have bowel cancer. This easy to perform early test could determine whether a person develops cancer yes or no. Below the abstract as published in the British Journal of Cancer.

Faecal tumor M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer

PD Hardt1, Mazurek2 S, M Toepler3, P Schlierbach3, RG Bretzel1, E Eigenbrodt2, and HU Kloer1 1Third Poli Clinic and Medical Department, Giessen University Hospital, Justus-Liebig University of Giessen, Rodthohl 6, 35392 Giessen, Germany
2Institute of Biochemistry and Endocrinology, Veterinary Faculty, University of Giessen, Frankfurter Strasse 100, 35392 Giessen, Germany 3Medical Department and Surgical Department of the Asklepios Clinic, Goethe Strasse 4, 35423 Lich, Germany
Correspondence to: Dr PD Hardt, E-mail: @ Philip.D.Hardt innere.med.uni-giessen.de

This work is dedicated to the memory of Professor Erich Eigenbrodt who died in June 2004. His fundamental research in tumor metabolism resulted in the development of tumor M2-PK testing and Their introduction for clinical applications.

Received 30 December 2003, revised 20 May 2004, accepted 7 June 2004, published online 13 July 2004

Proliferating cells, Especially tumor cells, express a special isoenzyme of pyruvate kinase, termed M2-PK, Which can-occure in a tetra meric form with a high affinity to ITS substrate, phosphoenolpyruvate (PEP), and in a dimeric form with a low PEP affinity . In tumor cells, the dimeric form is predominant and is therefore Usually termed Tumor M2-PK. The levels of Tumour M2-PK within-tumoren and in EDTA plasma correlate with late staging and the ability of the tumor cells to metastasis. Since colorectal tumoren must grow intraluminally, it appeared interesting to determining whethere Tumor M2-PK is detectable in the feces or tumor patient. Stool samples Were Tested by ELISA from controls without colorectal cancer and colorectal cancer patients. Whereas Tumor M2-PK Were low levels in the control group (mean value ± SEM: 3.3 ± 0.4, n = 144), They Were high in the case of colorectal cancer (56.1 ± 15.3, n = 60). At a cutoff value of 4 U ml-1, the sensitivity was 73%. TNM and Dukes' classification of the tumoren revealed a strong correlation Between faecal Tumour M2-PK levels and staging. The Determination of Tumor M2-PK in feces Provides a promising new screening tool for colorectal tumoren.